Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

(2020) A. Hochhaus et al.   LEUKEMIA

Response and Resistance to BCR-ABL1-Targeted Therapies

(2020) Theodore P. Braun et al.   CANCER CELL

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

(2020) Aleksandr Ianevski et al.   NUCLEIC ACIDS RESEARCH

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

(2018) Lorenzo Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

(2018) Susanne Saussele et al.   LANCET ONCOLOGY

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells

(2018) Zhaodong Li et al.   LEUKEMIA

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

(2018) Michele Massimino et al.   Molecular Cancer

T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system

(2018) Minori Tamai et al.   Scientific Reports

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

(2018) Donia M. Moujalled et al.   LEUKEMIA

MCL-1 inhibition in cancer treatment

(2018) Weiguo Xiang et al.   OncoTargets and Therapy

Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin

(2017) Yupeng Wang et al.   NATURE

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

(2017) Andrew A. Wylie et al.   NATURE

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

(2017) Andreas Hochhaus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells

(2017) H S Madapura et al.   ONCOGENE

Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death

(2017) Corey Rogers et al.   Nature Communications

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death

(2015) Jianjin Shi et al.   NATURE

Human Flt3 Is Expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor Stages to Maintain Cell Survival

(2014) Y. Kikushige et al.   JOURNAL OF IMMUNOLOGY

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Establishment And Characterization Of A Novel Philadelphia- Chromosoe Positive Chronic Myeloid Leukemia Cell Line, TCC-S, Expressing P210 And P190 BCR/ABL Transcripts But Missing Normal ABL Gene

(2010) Phan Nguyen Thanh Van et al.   Human Cell

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY